Darin E Jones, PhD

Research Program: Cancer Therapeutics Faculty Rank: Associate Professor Campus: University of Arkansas for Medical Sciences College: College of Pharmacy Department: Pharmaceutical Science

Cancer Research Interest

• Disease Site Focus: Brain, Breast, Gynecology, Leukemia/ Lymphoma
• Research Focus Area: Carcinogenesis
• Type of Research: Basic
• Research Interest Statement: We study essential proteins involved in DNA repair processes. Using fragment-based and computer-aided drug designtechniques, we are developing small molecule inhibitors and chemical tool compounds of these essential proteins to provide agreater understanding of the mechanisms of DNA repair processes and of chemotherapeutic drug resistance. Obtain access to institute supported resources to facilitate research program. Meet additional investigators with common interest to development potential collaborations.

Contact Information

• Email Address: DEJONES@UAMS.EDU
• Profiles Research Networking Software: View Profile

Recent Publications

• Brosey CA, Link TM, Shen R, [et al., including Jones DE]. Chemical screening by time-resolved X-ray scattering to discover allosteric probes. Nature chemical biology. 2024. PMID: 38671223. PMCID: PMC11358040.
• Puvvula J, Manz KE, Braun JM, [et al., including Jones DP]. Maternal and newborn metabolomic changes associated with urinary polycyclic aromatic hydrocarbon metabolite concentrations at delivery: an untargeted approach. Metabolomics : Official journal of the Metabolomic Society. 2023 20(1):6. PMID: 38095785.
• Shrum SA, Nukala U, Shrimali S, [et al., including Jones DE]. Tocotrienols Provide Radioprotection to Multiple Organ Systems through Complementary Mechanisms of Antioxidant and Signaling Effects. Antioxidants (Basel, Switzerland). 2023 12(11). PMID: 38001840. PMCID: PMC10668991.
• Syed A, Filandr F, Patterson-Fortin J, [et al., including Jones DE]. Novobiocin blocks nucleic acid binding to Polθ and inhibits stimulation of its ATPase activity. Nucleic acids research. 2023 51(18):9920-9937. PMID: 37665033. PMCID: PMC10570058.
• Brosey CA, Shen R, Moiani D, [et al., including Jones DE]. Applying HT-SAXS to chemical ligand screening. Methods in enzymology. 2023 678:331-350. PMID: 36641213. PMCID: PMC11239221.
• Mery DE, Compadre AJ, Ordóñez PE, [et al., including Jones DE]. Analysis of Plant-Plant Interactions Reveals the Presence of Potent Antileukemic Compounds. Molecules (Basel, Switzerland). 2022 27(9). PMID: 35566279. PMCID: PMC9105371.
• Ye Z, Xu S, Shi Y, [et al., including Jones DE]. GRB2 enforces homology-directed repair initiation by MRE11. Science advances. 2021 7(32). PMID: 34348893. PMCID: PMC8336959.
• Nguyen MT, Moiani D, Ahmed Z, [et al., including Jones DE]. An effective human uracil-DNA glycosylase inhibitor targets the open pre-catalytic active site conformation. Progress in biophysics and molecular biology. 2021. PMID: 33675849. PMCID: PMC8722130.
• Brosey CA, Houl JH, Katsonis P, [et al., including Jones DE]. Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors. Progress in biophysics and molecular biology. 2021. PMID: 33636189. PMCID: PMC7901392.
• Moiani D, Link TM, Brosey CA, [et al., including Jones DE]. An efficient chemical screening method for structure-based inhibitors to nucleic acid enzymes targeting the DNA repair-replication interface and SARS CoV-2. Methods in enzymology. 2021 661:407-431. PMID: 34776222. PMCID: PMC8474023.
• Ordóñez PE, Mery DE, Sharma KK, [et al., including Jones DE]. Synthesis, Crystallography, and Anti-Leukemic Activity of the Amino Adducts of Dehydroleucodine. Molecules (Basel, Switzerland). 2020 25(20). PMID: 33092263. PMCID: PMC7588005.
• Houl JH, Ye Z, Brosey CA, [et al., including Jones DE]. Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death. Nature communications. 2019 10(1):5654. PMID: 31827085. PMCID: PMC6906431.